Home › Companies › REATA PHARMACEUTICALS INC. › 2023-2024
Compiled from SEC Form N-PX filings and REATA PHARMACEUTICALS INC.’s Form 8-K, filed 2023-09-21 (Item 5.07 on EDGAR). Page generated 02 October 2026.
Proxy season: 2023-2024
Explore REATA PHARMACEUTICALS INC. in the interactive database Compare manager voting policies
These tallies are REATA PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2023-09-21 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Outcome |
|---|---|---|---|---|---|---|
| Proposal 1: Proposal No. 1 - The Merger Proposal : To approve and adopt the Agreement and Plan of Merger, dated as of July 28, 2023, as such agreement may be amended from time to time (the " Merger Agreement "), by and among Biogen Inc., a Delaware corporation | 41,461,455 | 39,094 | 34,360 | -- | 0 | Majority: yes |
| Proposal 2: Proposal No. 2 - The Advisory Compensation Proposal : To approve, on an advisory, non-binding basis, compensation that will or may be paid or become payable to Reata's named executive officers in connection with the Merger contemplated by the Merge | 28,023,999 | 12,977,053 | 533,857 | -- | 0 | Majority: yes |
| Proposal 3: Proposal No. 3 - The Adjournment Proposal : To approve to adjourn the Special Meeting to a later date if necessary and appropriate to solicit additional proxies if there are insufficient votes to adopt the Merger Agreement at the time of the Specia | 40,145,724 | 1,261,433 | 127,752 | -- | 0 | Majority: yes |
Source: REATA PHARMACEUTICALS INC., Form 8-K, filed with the SEC on 2023-09-21 — read the filing on EDGAR.
Each item below shows how the 265 asset managers that disclosed a REATA PHARMACEUTICALS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of REATA PHARMACEUTICALS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 14 wordings of this item as funds reported it.
68% Majority: yes · of votes cast
REATA PHARMACEUTICALS INC.’s own tally for this item (“Proposal 2: Proposal No. 2 - The Advisory Compensation Proposal : To approve, on an advisory, non-binding basis, compensation that will or may be paid or become payable to Reata's named executive officers in connection w”): 28,023,999 for, 12,977,053 against, per its Form 8-K filed 2023-09-21 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Share-of-outstanding not shown: votes cast exceed the reported share count, which usually means multiple share classes with different voting rights.
The 251 asset managers below cast 42% of the shares they voted on this item FOR (10,158,075 for, 14,175,994 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| CPMG Inc | 4,589,758 | 0 | 0 | 0 | For |
| Vanguard | 0 | 2,824,819 | 0 | 0 | Against |
| BlackRock | 8,903 | 1,736,521 | 0 | 0 | Against |
| Man Group plc | 0 | 1,596,120 | 0 | 0 | Against |
| Fidelity | 0 | 1,214,367 | 0 | 0 | Against |
| First Light Asset Management, LLC | 1,082,646 | 0 | 0 | 0 | For |
| FARALLON CAPITAL MANAGEMENT LLC | 1,061,032 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 0 | 607,391 | 0 | 0 | Against |
| State Street | 0 | 572,960 | 0 | 0 | Against |
| Invesco | 0 | 564,587 | 0 | 0 | Against |
| Charles Schwab | 0 | 435,984 | 0 | 0 | Against |
| Voya | 0 | 29,980 | 383,088 | 0 | Abstain |
| Blackstone Inc. | 340,793 | 0 | 0 | 0 | For |
| BALYASNY ASSET MANAGEMENT L.P. | 0 | 308,989 | 0 | 0 | Against |
| TimesSquare Capital Management, LLC | 274,468 | 0 | 0 | 0 | For |
| Magnetar Financial LLC | 0 | 250,421 | 0 | 0 | Against |
| HBK INVESTMENTS L P | 0 | 245,614 | 0 | 0 | Against |
| MPM BioImpact LLC | 233,691 | 0 | 0 | 0 | For |
| EMERALD MUTUAL FUND ADVISERS TRUST | 232,277 | 0 | 0 | 0 | For |
| WATER ISLAND CAPITAL LLC | 215,024 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 193,478 | 0 | 0 | 0 | For |
| Sofinnova Investments, Inc. | 141,598 | 48,668 | 0 | 0 | For |
| MERGER FUND | 189,620 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 0 | 169,253 | 0 | 0 | Against |
| UBS | 0 | 167,738 | 0 | 0 | Against |
Showing the 25 largest of 251 asset managers. See all 251 in the interactive database.
Combines 3 wordings of this item as funds reported it.
99.9% Majority: yes · of votes cast
REATA PHARMACEUTICALS INC.’s own tally for this item (“Proposal 1: Proposal No. 1 - The Merger Proposal : To approve and adopt the Agreement and Plan of Merger, dated as of July 28, 2023, as such agreement may be amended from time to time (the " Merger Agreement "), by and a”): 41,461,455 for, 39,094 against, per its Form 8-K filed 2023-09-21 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Share-of-outstanding not shown: votes cast exceed the reported share count, which usually means multiple share classes with different voting rights.
The 77 asset managers below cast 100% of the shares they voted on this item FOR (7,821,025 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,777,206 | 0 | 0 | 0 | For |
| BlackRock | 1,131,027 | 0 | 0 | 0 | For |
| Fidelity | 624,911 | 0 | 0 | 0 | For |
| TimesSquare Capital Management, LLC | 274,468 | 0 | 0 | 0 | For |
| Invesco | 251,716 | 0 | 0 | 0 | For |
| Charles Schwab | 217,992 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 193,478 | 0 | 0 | 0 | For |
| Voya | 191,544 | 0 | 0 | 0 | For |
| MERGER FUND | 189,620 | 0 | 0 | 0 | For |
| New York Life | 167,391 | 0 | 0 | 0 | For |
| ARBITRAGE FUNDS | 150,311 | 0 | 0 | 0 | For |
| NEXPOINT FUNDS I | 148,800 | 0 | 0 | 0 | For |
| FINANCIAL INVESTORS TRUST | 135,440 | 0 | 0 | 0 | For |
| Investment Managers Series Trust II | 99,879 | 0 | 0 | 0 | For |
| State Street | 96,154 | 0 | 0 | 0 | For |
| Principal | 93,645 | 0 | 0 | 0 | For |
| Equitable | 55,180 | 0 | 32,500 | 0 | For |
| Columbia Threadneedle | 80,997 | 0 | 0 | 0 | For |
| TIAA | 79,284 | 0 | 0 | 0 | For |
| Goldman Sachs | 53,965 | 0 | 0 | 0 | For |
| Jackson National | 52,392 | 0 | 0 | 0 | For |
| American Century | 51,846 | 0 | 0 | 0 | For |
| JPMorgan | 50,873 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 49,408 | 0 | 0 | 0 | For |
| ALGER INSTITUTIONAL FUNDS | 38,692 | 0 | 0 | 0 | For |
Showing the 25 largest of 77 asset managers. See all 77 in the interactive database.
Combines 2 wordings of this item as funds reported it.
97% Majority: yes · of votes cast
REATA PHARMACEUTICALS INC.’s own tally for this item (“Proposal 3: Proposal No. 3 - The Adjournment Proposal : To approve to adjourn the Special Meeting to a later date if necessary and appropriate to solicit additional proxies if there are insufficient votes to adopt the Me”): 40,145,724 for, 1,261,433 against, per its Form 8-K filed 2023-09-21 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Share-of-outstanding not shown: votes cast exceed the reported share count, which usually means multiple share classes with different voting rights.
The 76 asset managers below cast 91% of the shares they voted on this item FOR (7,115,927 for, 705,049 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,777,206 | 0 | 0 | 0 | For |
| BlackRock | 1,131,027 | 0 | 0 | 0 | For |
| Fidelity | 47,795 | 577,116 | 0 | 0 | Against |
| TimesSquare Capital Management, LLC | 274,468 | 0 | 0 | 0 | For |
| Invesco | 251,716 | 0 | 0 | 0 | For |
| Charles Schwab | 217,992 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 193,478 | 0 | 0 | 0 | For |
| Voya | 191,544 | 0 | 0 | 0 | For |
| MERGER FUND | 189,620 | 0 | 0 | 0 | For |
| New York Life | 167,391 | 0 | 0 | 0 | For |
| ARBITRAGE FUNDS | 150,311 | 0 | 0 | 0 | For |
| NEXPOINT FUNDS I | 148,800 | 0 | 0 | 0 | For |
| FINANCIAL INVESTORS TRUST | 135,440 | 0 | 0 | 0 | For |
| Investment Managers Series Trust II | 99,879 | 0 | 0 | 0 | For |
| State Street | 0 | 96,154 | 0 | 0 | Against |
| Principal | 93,645 | 0 | 0 | 0 | For |
| Equitable | 55,180 | 0 | 32,500 | 0 | For |
| Columbia Threadneedle | 80,997 | 0 | 0 | 0 | For |
| TIAA | 79,284 | 0 | 0 | 0 | For |
| Goldman Sachs | 53,965 | 0 | 0 | 0 | For |
| Jackson National | 52,392 | 0 | 0 | 0 | For |
| American Century | 51,846 | 0 | 0 | 0 | For |
| JPMorgan | 50,873 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 49,408 | 0 | 0 | 0 | For |
| ALGER INSTITUTIONAL FUNDS | 38,692 | 0 | 0 | 0 | For |
Showing the 25 largest of 76 asset managers. See all 76 in the interactive database.
Combines 2 wordings of this item as funds reported it.
0% fund support · no official result
The 7 asset managers below cast 0% of the shares they voted on this item FOR (0 for, 1,117,710 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 0 | 1,031,125 | 0 | 0 | Against |
| JPMorgan | 0 | 51,908 | 0 | 0 | Against |
| Walleye Capital LLC | 0 | 33,682 | 0 | 0 | Against |
| Walleye Trading LLC | 0 | 671 | 0 | 0 | Against |
| Desjardins Global Asset Management Inc. | 0 | 291 | 0 | 0 | Against |
| TD ASSET MANAGEMENT INC | 0 | 33 | 0 | 0 | Against |
| Taconic Capital Advisors LP | 0 | 0 | 0 | 0 | -- |
Ranked by the number of REATA PHARMACEUTICALS INC. shares each manager voted on the most widely held ballot item of the 2023-2024 meeting, shown as a share of the 37,311,872 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | CPMG Inc | 12.30% |
| 2 | Vanguard | 7.57% |
| 3 | BlackRock | 4.68% |
| 4 | Man Group plc | 4.28% |
| 5 | Fidelity | 3.25% |
| 6 | First Light Asset Management, LLC | 2.90% |
| 7 | FARALLON CAPITAL MANAGEMENT LLC | 2.84% |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 1.63% |
| 9 | State Street | 1.54% |
| 10 | Invesco | 1.51% |
Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).
| Holder | % outstanding | Disclosure |
|---|---|---|
| Norges Bank | 0.44% | 13F |
Percentages above are of 37,311,872 shares outstanding, as reported by REATA PHARMACEUTICALS INC. on its Form 10-Q dated 2023-06-30 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from REATA PHARMACEUTICALS INC.’s 10-Q dated 2023-06-30. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.
At REATA PHARMACEUTICALS INC.'s shareholder meeting held 2023-09-21, in the 2023-2024 proxy season, 265 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,033 separate fund positions. Their filings are grouped here into 4 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, on an advisory, non- binding basis, compensation that will or may be paid or become… — FOR was 68% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: REATA PHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2023-09-21.
REATA PHARMACEUTICALS INC. proxy season coverage: 2023-2024 (this page).